Gobom, Johan

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 204

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Gobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM)

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 146

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 132

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.

Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 122

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ 38 , Aβ 40 , and Aβ 42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsAdvanced Proteomics Techniques and Applications

Cited by 105

An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research

Advanced Proteomics Techniques and ApplicationsAlzheimer's disease research and treatments

Cited by 100

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 82

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease

Skillbäck, T., Mattsson, N., Hansson, K., Mirgorodskaya, E., Dahlén, R., van der Flier, W., Scheltens, P., Duits, F., Hansson, O., Teunissen, C., et al. (2017) · Scientific Reports

Advanced Proteomics Techniques and ApplicationsAlzheimer's disease research and treatments

Cited by 61

Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates

Russell, C. L., Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., & Pike, I. (2016) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsAdvanced Proteomics Techniques and Applications

Cited by 52

Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics

Magdalinou, N. K., Noyce, A. J., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M., Blennow, K., Morris, H. R., Skillbäck, T., Warner, T. T., et al. (2017) · Parkinsonism & Related Disorders

Parkinson's Disease Mechanisms and TreatmentsAdvanced Proteomics Techniques and Applications

Cited by 49

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia

Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 39